{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
sildenafil
to a specific field?
Status:
Possibly Marketed Outside US
Source:
NCT00555087: Phase 4 Interventional Unknown status Erectile Dysfunction
(2007)
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2013)
Source:
ANDA078380
(2013)
Source URL:
First approved in 1998
Source:
NDA020895
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Sildenafil (Viagra, Revatio) is a PDE5 inhibitor which was approved by FDA for the treatment of erectile disfunction and adults with pulmonary arterial hypertension. Upon administration sildenafil inhibits PDE5 and results in elevated level of cyclic guanosine monophosphate and smooth muscle relaxation.
Status:
US Approved Rx
(2013)
Source:
ANDA078380
(2013)
Source URL:
First approved in 1998
Source:
NDA020895
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Sildenafil (Viagra, Revatio) is a PDE5 inhibitor which was approved by FDA for the treatment of erectile disfunction and adults with pulmonary arterial hypertension. Upon administration sildenafil inhibits PDE5 and results in elevated level of cyclic guanosine monophosphate and smooth muscle relaxation.
